Loading clinical trials...

Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients | Clinical Trials | Clareo Health

UNKNOWNNA

Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients

NCT01237275•Samsung Medical Center

View on ClinicalTrials.gov

Summary

First, the investigators examined the functional relevance of serotonin transporter polymorphisms by quantifying the activity of serotonin transporter in blood platelets of genotyped healthy volunteers and patients with major depression. Second, the investigators studied response to SSRIs in relation to 5-HTTLPR genotype and also to the functional expression of 5-HTT in platelets.

Detailed Description

The purpose of this study is 1. to determine whether serotonin transporter genotypic or functional differences between depressive patients and normal controls were existed. 2. to determine the relationship between serotonin transporter polymorphisms and serotonin transporter functional expression. 3. to determine whether genomic or functional differences between drug responders and nonresponders predict the response of antidepressant

Eligibility

Age

19 - 89 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.
•interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians

Exclusion Criteria

•received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks
•potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

Locations (1)

Samsung Medical Center

Kangnam, Seoul, South Korea

Key Dates

Start Date

October 1, 1999

Primary Completion Date

December 1, 2003

Completion Date

December 1, 2016

Last Updated

December 31, 2015

Enrollment

300

ESTIMATED participants

Conditions

DepressionContinuous Antidepressant AbuseAdverse Reaction to Drug

Interventions

SSRI treated group

DRUG

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

NCT07360600

ParentsChildren With Disabilities+2 more

View study

RECRUITINGPHASE3

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

NCT06793397

Major Depressive Disorder (MDD)Depression in Adults+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 31, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients

Inclusion Criteria

Exclusion Criteria

ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Readiness and Progress in Emotion Regulation Therapy

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression

Serotonin-norepinephrine Reuptake Inhibitor in Prophylaxis of Depression Following Fragility Fractures